FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158343048> ?p ?o ?g. }

• W2158343048 endingPage "284" @default.
• W2158343048 startingPage "278" @default.
• W2158343048 abstract "(62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone) was developed as a hypoxic radiotracer in PET. We compared imaging features among MR imaging and (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone)-PET, FDG-PET, and L-methyl-[(11)C]methionine)-PET in gliomas.We enrolled 23 patients who underwent (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone)-PET and FDG-PET and 19 (82.6%) who underwent L-methyl-[(11)C]methionine)-PET, with all 23 patients undergoing surgery and their diagnosis being then confirmed by histologic examination as a glioma. Semiquantitative and volumetric analysis were used for the comparison.There were 10 newly diagnosed glioblastoma multiforme and 13 nonglioblastoma multiforme (grades II and III), including 4 recurrences without any adjuvant treatment. The maximum standardized uptake value and tumor/background ratios of (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone), as well as L-methyl-[(11)C]methionine, were significantly higher in glioblastoma multiforme than in nonglioblastoma multiforme (P = .03 and P = .03, respectively); no significant differences were observed on FDG. At a tumor/background ratio cutoff threshold of 1.9, (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone) was most predictive of glioblastoma multiforme, with 90.0% sensitivity and 76.9% specificity. The positive and negative predictive values, respectively, for glioblastoma multiforme were 75.0% and 85.7% on (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone), 83.3% and 60.0% on L-methyl-[(11)C]methionine, and 72.7% and 75.0% on MR imaging. In glioblastoma multiforme, volumetric analysis demonstrated that (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone) uptake had significant correlations with FDG (r = 0.68, P = .03) and L-methyl-[(11)C]methionine (r = 0.87, P = .03). However, the (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone)-active region was heterogeneously distributed in 50.0% (5/10) of FDG-active and 0% (0/6) of L-methyl-[(11)C]methionine)-active regions.(62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone) may be a practical radiotracer in the prediction of glioblastoma multiforme. In addition to FDG-PET, L-methyl-[(11)C]methionine)-PET, and MR imaging, (62)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone)-PET may provide intratumoral hypoxic information useful in establishing targeted therapeutic strategies for patients with glioblastoma multiforme." @default.
• W2158343048 created "2016-06-24" @default.
• W2158343048 creator A5003278874 @default.
• W2158343048 creator A5007113453 @default.
• W2158343048 creator A5007932714 @default.
• W2158343048 creator A5014669732 @default.
• W2158343048 creator A5034162457 @default.
• W2158343048 creator A5034642477 @default.
• W2158343048 creator A5035569208 @default.
• W2158343048 creator A5054221876 @default.
• W2158343048 creator A5078203308 @default.
• W2158343048 creator A5083301071 @default.
• W2158343048 date "2013-08-08" @default.
• W2158343048 modified "2023-09-27" @default.
• W2158343048 title "62Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) PET in Human Gliomas: Comparative Study with [18F]Fluorodeoxyglucose and L-Methyl-[11C]Methionine PET" @default.
• W2158343048 cites W1965254121 @default.
• W2158343048 cites W2015602031 @default.
• W2158343048 cites W2023758771 @default.
• W2158343048 cites W2030578525 @default.
• W2158343048 cites W2031022390 @default.
• W2158343048 cites W2045407003 @default.
• W2158343048 cites W2049395088 @default.
• W2158343048 cites W2055145844 @default.
• W2158343048 cites W2057343401 @default.
• W2158343048 cites W2059051110 @default.
• W2158343048 cites W2076066580 @default.
• W2158343048 cites W2079034377 @default.
• W2158343048 cites W2087073880 @default.
• W2158343048 cites W2098417097 @default.
• W2158343048 cites W2114397483 @default.
• W2158343048 cites W2118981922 @default.
• W2158343048 cites W2145640842 @default.
• W2158343048 cites W2158636665 @default.
• W2158343048 cites W2158794894 @default.
• W2158343048 cites W2160382843 @default.
• W2158343048 cites W2165283491 @default.
• W2158343048 cites W2171751255 @default.
• W2158343048 cites W40044024 @default.
• W2158343048 cites W4244344354 @default.
• W2158343048 doi "https://doi.org/10.3174/ajnr.a3679" @default.
• W2158343048 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7965738" @default.
• W2158343048 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23928140" @default.
• W2158343048 hasPublicationYear "2013" @default.
• W2158343048 type Work @default.
• W2158343048 sameAs 2158343048 @default.
• W2158343048 citedByCount "17" @default.
• W2158343048 countsByYear W21583430482016 @default.
• W2158343048 countsByYear W21583430482018 @default.
• W2158343048 countsByYear W21583430482019 @default.
• W2158343048 countsByYear W21583430482020 @default.
• W2158343048 countsByYear W21583430482021 @default.
• W2158343048 countsByYear W21583430482022 @default.
• W2158343048 countsByYear W21583430482023 @default.
• W2158343048 crossrefType "journal-article" @default.
• W2158343048 hasAuthorship W2158343048A5003278874 @default.
• W2158343048 hasAuthorship W2158343048A5007113453 @default.
• W2158343048 hasAuthorship W2158343048A5007932714 @default.
• W2158343048 hasAuthorship W2158343048A5014669732 @default.
• W2158343048 hasAuthorship W2158343048A5034162457 @default.
• W2158343048 hasAuthorship W2158343048A5034642477 @default.
• W2158343048 hasAuthorship W2158343048A5035569208 @default.
• W2158343048 hasAuthorship W2158343048A5054221876 @default.
• W2158343048 hasAuthorship W2158343048A5078203308 @default.
• W2158343048 hasAuthorship W2158343048A5083301071 @default.
• W2158343048 hasBestOaLocation W21583430481 @default.
• W2158343048 hasConcept C185592680 @default.
• W2158343048 hasConcept C2775842073 @default.
• W2158343048 hasConcept C2776194525 @default.
• W2158343048 hasConcept C2778227246 @default.
• W2158343048 hasConcept C2779529559 @default.
• W2158343048 hasConcept C2780912031 @default.
• W2158343048 hasConcept C2989005 @default.
• W2158343048 hasConcept C502942594 @default.
• W2158343048 hasConcept C515207424 @default.
• W2158343048 hasConcept C55493867 @default.
• W2158343048 hasConcept C71924100 @default.
• W2158343048 hasConceptScore W2158343048C185592680 @default.
• W2158343048 hasConceptScore W2158343048C2775842073 @default.
• W2158343048 hasConceptScore W2158343048C2776194525 @default.
• W2158343048 hasConceptScore W2158343048C2778227246 @default.
• W2158343048 hasConceptScore W2158343048C2779529559 @default.
• W2158343048 hasConceptScore W2158343048C2780912031 @default.
• W2158343048 hasConceptScore W2158343048C2989005 @default.
• W2158343048 hasConceptScore W2158343048C502942594 @default.
• W2158343048 hasConceptScore W2158343048C515207424 @default.
• W2158343048 hasConceptScore W2158343048C55493867 @default.
• W2158343048 hasConceptScore W2158343048C71924100 @default.
• W2158343048 hasIssue "2" @default.
• W2158343048 hasLocation W21583430481 @default.
• W2158343048 hasLocation W21583430482 @default.
• W2158343048 hasLocation W21583430483 @default.
• W2158343048 hasOpenAccess W2158343048 @default.
• W2158343048 hasPrimaryLocation W21583430481 @default.
• W2158343048 hasRelatedWork W2150340231 @default.
• W2158343048 hasRelatedWork W2159281512 @default.
• W2158343048 hasRelatedWork W2740568283 @default.
• W2158343048 hasRelatedWork W2894720858 @default.
• W2158343048 hasRelatedWork W2977275234 @default.

• next